ALDA to Request Human Trials for Athlete's Foot With New T36(R) Anti-Inflammatory, Anti-Microbial Therapeutic

ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") announces that it has
received positive results from BioScience Laboratories, Inc. for the T36(R)
formulation which was tested against two species of fungi responsible for
athlete's foot, Trichophyton mentagrophytes and Trichophyton rubrum. T36(R)
achieved a complete kill of both organisms within 5 minutes, the shortest time
required by the FDA.


Completion of these tests allows ALDA to approach Health Canada with a Clinical
Trial Application ("CTA") for testing of the new T36(R) anti-inflammatory,
anti-microbial formulation against athlete's foot. Once the CTA has been
approved by Health Canada, human trials can begin. ALDA can now also request a
"pre-IND" (pre-Investigational New Drug) meeting with the FDA for human tests of
the new T36(R) formulation against athlete's foot. From this meeting, any
additional tests required by the FDA before human trials can begin will be
clarified.


Dr. Terrance Owen, President & CEO, states, "The new T36(R) anti-inflammatory
anti-microbial formulation is an important new product in our arsenal of
infection control therapeutics. As announced in a news release dated March 25,
2008, this new product has already been successfully tested against a number of
topical infections, including athlete's foot, diaper rash and eczema and we have
filed a PCT patent application. Athlete's foot is an ideal indication to pursue
initially since it is relatively easy to test, represents a large market and
will allow physicians to prescribe the product 'off-label' for other topical
infections once it has been approved. We are very excited by the prospect that
we are now able to request human trials and we are starting the preparation of
the protocols immediately."


About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived
from its patented T36(R) technology. The company trades on the TSX Venture
Exchange under the symbol APH.


Terrance G. Owen, Ph.D., MBA

President, CEO and Director

ALDA Pharmaceuticals Corp.